Lymphedema Diagnostics Market Size to Reach USD 75.17 Mn by 2034

Vantage Market Research releases its latest comprehensive report on the ‘Global Lymphedema Diagnostics Market’ with a forecast period of 2025-2034. In 2023, the global lymphedema diagnostics market size was USD 34.63 million, and is calculated at USD 37.16 million in 2024. The market is projected to reach USD 75.17 million in 2034, and register a revenue CAGR of 7.3% over the forecast period (2025-2034).

Market Overview:

Global Lymphedema (LE) diagnostics market revenue growth is driven by rising prevalence of cancer and need for radiation and chemotherapy treatments, increasing awareness regarding the conditions and symptoms among healthcare personnel and medical practitioners, improved capability for early detection of lymphatic diseases, advancements in diagnostic imaging technologies, and increasing healthcare investment worldwide. 

Growth of the global lymphedema diagnostics market is also supported to a major extent by a rapidly aging global populations, high prevalence of cancer-related lymphedema, increase in cardiac disease, and technological advancements and innovation in the medical field. In addition, improved access to healthcare, supportive government policies, increasing integration of Artificial Intelligence (AI) and adoption technologically-driven diagnostics in the healthcare sector, and increasing funding in research initiatives are factors expected to continue to drive market growth over the forecast period.

Lymphedema (LE) is a condition caused by impaired lymphatic drainage, and does not have a cure as of now. The condition leads to painful swelling and fluid retention, primarily in the limbs, and can occur at any time or stage. Lymphedema can emerge post-surgery or following radiation to the lymph nodes, and the risk continues for the rest of an individual’s life. The symptoms can be treated to reduce swelling and improve function. Besides affecting persons who have undergone cancer treatments, lymphedema can emerge due to surgical trauma, contracted infections, or occur in those with a genetic predisposition. 

Early diagnosis of LE is crucial to prevent complications such as infections, fibrosis, and reduce mobility. The condition predominantly affects adults and the elderly, with increased prevalence among breast, prostate, and gynecological cancer survivors due to lymph node removal or radiation therapy. Also, impaired lymphatic function can contribute to cardiovascular issues like congestive heart failure by hindering proper fluid drainage and potentially causing fluid buildup in the body, particularly in the legs. Recent research also links lymphatic dysfunction to the development of other cardiovascular diseases like atherosclerosis and hypertension. 

Diagnostic methods have evolved significantly, incorporating advanced imaging technologies lymphoscintigraphy, Magnetic Resonance Imaging (MRI), ultrasound imaging, Near IR fluorescence imaging, Computed Tomography, X-Ray lymphography, and bioimpedance analysis. These technologies and diagnostic techniques help to assess lymphatic function and visualize fluid accumulation. New trends, such as AI-enhanced imaging and the development of biomarkers, are streamlining diagnostic accuracy, reducing human error, and enabling personalized treatment approaches. Treatment for lymphedema generally includes physical therapy, compression garments, and, in severe cases, surgery, while promising medications and novel therapeutics are emerging to alleviate symptoms and slow progression.

Some Key Takeaways:

• Among the regional markets, the North America lymphedema diagnostics market continues to account for largest revenue share, and this trend is expected to gain momentum over the forecast period. 
• In the Europe lymphedema diagnostics market, Germany and the UK are major revenue contributors, owing to high healthcare investments and R&D efforts focused on innovative diagnostic solutions.
• The lymphoscintigraphy segment among the technology segments is expected to account for largest revenue share over the forecast period.
• The secondary lymphedema diagnosis segment is expected to account for largest revenue share among the diagnosis type segments over the forecast period. 
• The hospitals segment are expected to account for largest revenue share among end-user segments over the forecast period.
• The global lymphedema diagnostics market landscape is highly competitive, with leading companies leveraging strategic initiatives to strengthen their market positions and cater to evolving demand in the medical field.
• Some leading companies include GE Healthcare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, and Stryker, with other prominent companies such as Fluoptics, Shimadzu, and United Imaging Healthcare gaining traction.   

Company List:

• Siemens Healthineers 
• GE Healthcare
• Canon Medical Systems
• Stryker Corporation
• ImpediMed Ltd.
• Shimadzu Corporation
• Hitachi Ltd.
• Fluoptics
• Philips Healthcare
• L-Dex Instruments
• Mindray Medical International Ltd.
• AIROS Medical
• Bayer AG
• Johnson & Johnson
• Roche Diagnostics

Recent Developments:

• July 31, 2024: The Advanced Research Projects Agency for Health (ARPA-H), which is an agency within the US Department of Health and Human Services (HHS), announced the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. The program aims to develop physical, pharmacologic, gene, and cell-based therapeutic interventions to treat primary and rare Lymphatic Disease (LD) and chronic conditions complicated by lymphatic dysfunction. GLIDE’s forthcoming Innovative Solutions Opening (ISO) will address two critical challenges in lymphatic disease treatment - decompression, and repair and regeneration - through two technical areas: Restore Flow through Physical Interventions and Normalize Function through Targeted Pharmacologic, Gene and Cell Therapies. 
• January 1, 2024: The Lymphedema Treatment Act, which is a federal law passed by Congress on December 23, 2022, was put into effect on January 1, 2024, to improve Medicare insurance coverage for the medically necessary, doctor-prescribed compression supplies that are crucial for lymphedema treatment. Previously, Medicare and other similar policies did not cover doctor-prescribed compression supplies used daily, and these critical supplies are high-cost without insurance assistance, and affordability challenges resulted in a number of patients experiencing worsening progression of the condition. Asa result of the act being passed, Medicare covers lymphedema compression garments through a new benefit category, which includes standard and custom-fitted compression garments, wraps, and nighttime products, and authorized practitioners can prescribe these items to treat lymphedema.
• December 2023: The National Heart, Lung, and Blood Institute (NHLBI) launched the National Commission on Lymphatic Diseases (NCLD). The NCLD's purpose is to improve the health and care of people with lymphatic diseases by identifying gaps and opportunities in lymphatic science, stimulating research, evaluating obstacles to improving the prevention, diagnosis, and treatment of lymphatic diseases. It was requested by the lymphatic community and assembled with support from across the National Institutes of Health (NIH) in response to a congressional directive to establish a national body to advance lymphatics research.

Lymphedema Diagnostics Market Segmentation:

By Technology:

• Lymphoscintigraphy
• Magnetic Resonance Imaging (MRI)
• Ultrasound Imaging
• Near IR Fluorescence Imaging
• Computed Tomography
• X-Ray Lymphography
• Bioimpedance Analysis 

By Diagnosis Type:

• Primary Lymphedema Diagnosis
• Secondary Lymphedema Diagnosis
• Other 

By End-User:

• Hospitals, Diagnostic Centers
• Research & Academic Institutions
• Other

Regional Segmentation: 

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Rest of Latin America 

Middle East & Africa

• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA